The bystander effect of Treg depletion

Why modality could be critical for Treg-targeted therapies

Limiting bystander effects of immunosuppressive Treg-targeting therapies may be crucial for their antitumor efficacy, according to data released last week at the Society for Immunotherapy of Cancer meeting.

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) presented Phase I and Phase I/II data on Nov.

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE